Treasurer of the State of North Carolina Buys 44,145 Shares of Pfizer Inc. (NYSE:PFE)

Treasurer of the State of North Carolina lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,849,342 shares of the biopharmaceutical company's stock after purchasing an additional 44,145 shares during the quarter. Treasurer of the State of North Carolina owned about 0.05% of Pfizer worth $75,593,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Executive Wealth Management LLC bought a new stake in shares of Pfizer during the 3rd quarter worth $476,000. Coldstream Capital Management Inc. lifted its stake in Pfizer by 14.3% during the third quarter. Coldstream Capital Management Inc. now owns 108,212 shares of the biopharmaceutical company's stock worth $3,114,000 after purchasing an additional 13,535 shares during the last quarter. Brown Financial Advisors lifted its stake in Pfizer by 74.1% during the third quarter. Brown Financial Advisors now owns 43,888 shares of the biopharmaceutical company's stock worth $1,270,000 after purchasing an additional 18,684 shares during the last quarter. Financial Avengers Inc. boosted its holdings in shares of Pfizer by 52.1% in the 3rd quarter. Financial Avengers Inc. now owns 27,942 shares of the biopharmaceutical company's stock worth $809,000 after purchasing an additional 9,568 shares in the last quarter. Finally, Neo Ivy Capital Management increased its position in shares of Pfizer by 1,261.5% during the 3rd quarter. Neo Ivy Capital Management now owns 77,168 shares of the biopharmaceutical company's stock valued at $2,234,000 after purchasing an additional 71,500 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Trading Up 0.6 %

NYSE:PFE traded up $0.14 during trading hours on Monday, hitting $22.05. The company had a trading volume of 26,674,615 shares, compared to its average volume of 40,187,113. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a 50-day moving average price of $25.25 and a 200 day moving average price of $26.38. The company has a market capitalization of $125.06 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 earnings per share. Pfizer's quarterly revenue was up 24.7% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on PFE shares. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, UBS Group decreased their price objective on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.